BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 8834886)

  • 1. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice.
    Ji B; Perani EG; Petinom C; Grosset JH
    Antimicrob Agents Chemother; 1996 Feb; 40(2):393-9. PubMed ID: 8834886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice.
    Ji B; Perani EG; Petinon C; Grosset JH
    Int J Lepr Other Mycobact Dis; 1992 Dec; 60(4):556-61. PubMed ID: 1338596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients.
    Ji B; Jamet P; Perani EG; Sow S; Lienhardt C; Petinon C; Grosset JH
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2137-41. PubMed ID: 8878595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy.
    Ji B; Grosset J
    Lepr Rev; 2000 Dec; 71 Suppl():S81-7. PubMed ID: 11201894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients.
    Ji B; Sow S; Perani E; Lienhardt C; Diderot V; Grosset J
    Antimicrob Agents Chemother; 1998 May; 42(5):1115-20. PubMed ID: 9593137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.
    Consigny S; Bentoucha A; Bonnafous P; Grosset J; Ji B
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2919-21. PubMed ID: 10991891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy.
    Banerjee DK; McDermott-Lancaster RD; McKenzie S
    Antimicrob Agents Chemother; 1997 Feb; 41(2):326-30. PubMed ID: 9021187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of New Antibacterial Drugs and their Combinations in a Murine Model to Identify Short Duration Alternative Chemotherapy for Leprosy.
    Arumugam S; Joseph P; Ponnaiya J; Richard J; Das M; Chaitanya VS; Ebenezer M
    Indian J Lepr; 2016; 88(3):159-76. PubMed ID: 30207441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice.
    Xiong JH; Ji B; Perani EG; Pétinon C; Grosset JH
    Int J Lepr Other Mycobact Dis; 1994 Mar; 62(1):37-42. PubMed ID: 8189087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
    Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
    Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An experimental study to evaluate the bactericidal activity of ofloxacin against an established Mycobacterium leprae infection.
    Banerjee DK; McDermott-Lancaster RD
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):410-5. PubMed ID: 1474279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
    Mane I; Cartel JL; Grosset JH
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose treatment for paucibacillary leprosy; clinical problems and management.
    Pai VV; Bulchand HO; Revankar CR; Ganapati R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):310-2. PubMed ID: 10575414
    [No Abstract]   [Full Text] [Related]  

  • 14. Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up.
    Ganapati R; Revankar CR; Pai VV; Kingsley S
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):308-9. PubMed ID: 10575413
    [No Abstract]   [Full Text] [Related]  

  • 15. Single-dose treatment for paucibacillary leprosy; field implications.
    Revankar CR; Pai VV; Samy MS; Ganapati R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):312-4. PubMed ID: 10575415
    [No Abstract]   [Full Text] [Related]  

  • 16. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
    Matsuoka M; Kashiwabara Y; Namisato M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks.
    Ji B; Jamet P; Sow S; Perani EG; Traore I; Grosset JH
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1953-6. PubMed ID: 9303392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.
    Lenz SM; Collins JH; Ray NA; Hagge DA; Lahiri R; Adams LB
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008583. PubMed ID: 32936818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy.
    Grosset JH; Ji BH; Guelpa-Lauras CC; Perani EG; N'Deli LN
    Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):281-95. PubMed ID: 2198315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
    Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.